Phosphate binders are a major source of pill burden for CKD Stage 5 patients. With treatments, such as FOSRENOL, patients with hyperphosphatemia may be able to reduce their pill burden to as few as one tablet with each meal.* In fact, FOSRENOL has the lowest pill burden of all phosphate binders, which may aid in adherence and reduce treatment costs.
"Shire is committed to offering its effective, noncalcium, nonresin
phosphate binder, FOSRENOL, to CKD Stage 5 patients who need assistance
with the complications of elevated serum phosphorus," said Joseph Schlitz,
vice president, US Renal Business, Shire Pharmaceuticals. "Knowing the
evolving needs of the CKD community, we are continuing to improve the
product through new formulations and more user-friendly packaging. We hope
the combination of these efforts and the On Track program will provide
patients with the resources they require to help them adhere to their
hyperphosphatemia management regimens."
For More Information, Contact:
Phosphorus, an element found in nearly all foods, is absorbed from the
gastrointestinal tract into the bloodstream. When the kidneys fail, they no
longer effectively remove phosphorus. While the normal adult range for
phosphorus is 2.5 to 4.5 mg/dL, the blood phosphorus levels of many
patients on dialysis often exceed 6.5 mg/dL. Such levels have been linked
to a significantly higher morbidity and mortality risk for patients who
have undergone at least one year of dialysis. Research has shown that for
each mg/dL increase in mean serum phosphor
|SOURCE Shire Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved